跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
明诺凯 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Tafasitamab for Injection
Approved
生物制品
Tafasitamab for Injection
Incyte Biosciences Distribution B.V.
🇨🇳 National Medical Products Administration
Approval Date
May 13, 2025
Approval ID
8jhFVa6tfYV
Company
Incyte Biosciences Distribution B.V.
Type
生物制品
Approval Details
Approval Id
8jhFVa6tfYV
Approval Number
国药准字SJ20250018
Generic Name
注射用坦昔妥单抗
Generic Name En
Tafasitamab for Injection
Trade Name
明诺凯
Drug Type
生物制品
Dosage Form
注射剂
Strength
200mg/瓶
Reg Date
2025-05-13
Expired Date
2030-05-12
Company Name
Incyte Biosciences Distribution B.V.
Production Company Name
Baxter Oncology GmbH
Company Detail Path
/organization/incyte-biosciences-distribution-b-v
Production Company Detail Path
/organization/baxter-oncology-gmbh
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
May 13, 2025
Approval ID
8jhFVa6tfYV
Type
生物制品
Back to NMPA Approvals